AbbVie (NYSE: ABBV) SVP awarded options and performance-based stock grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AbbVie Inc. senior vice president and controller David Ryan Purdue reported multiple equity awards and holdings changes. On February 18, 2026, he acquired an option to buy 4,875 shares of AbbVie common stock at an exercise price set by the company’s incentive plan, recorded at $0.00 per share for reporting purposes.
On the same date, he also acquired several blocks of AbbVie common stock as grants or awards: 2,505 shares, 890 shares, 1,292 shares, and 1,384 shares, all reported at $0.00 per share as they were issued under performance-based share and restricted stock unit awards. Footnotes explain these awards were tied to earnings per share, relative total shareholder return, and relative return on equity goals, with vesting confirmed by AbbVie’s Compensation Committee and the shares scheduled to be issued on February 28, 2026.
The filing also notes 543 shares of AbbVie common stock held indirectly through a profit sharing trust as part of the AbbVie savings program as of February 20, 2026, including shares acquired via dividend reinvestment. The employee stock option vests in annual increments of 1,625 shares on February 18 of 2027, 2028, and 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Purdue David Ryan
Role
SVP, Controller
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (Right to buy) | 4,875 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 2,505 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 890 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 1,292 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 1,384 | $0.00 | -- |
| holding | Common Stock, $0.01 par value | -- | -- | -- |
Holdings After Transaction:
Option (Right to buy) — 4,875 shares (Direct);
Common Stock, $0.01 par value — 7,010 shares (Direct);
Common Stock, $0.01 par value — 543 shares (Indirect, Profit sharing trust)
Footnotes (1)
- Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 1,625 on February 18, 2027, 1,625 on February 18, 2028, and 1,625 on February 18, 2029.
FAQ
What insider transactions did AbbVie (ABBV) executive David Ryan Purdue report?
David Ryan Purdue reported multiple equity awards on February 18, 2026, including an option for 4,875 shares and several grants of AbbVie common stock. These were issued at $0.00 per share as compensation awards tied to performance goals and long-term incentive programs.
How many AbbVie (ABBV) stock options did the SVP, Controller receive in this Form 4?
The AbbVie SVP, Controller received an employee stock option covering 4,875 AbbVie common shares. The option was granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and becomes exercisable in three equal annual installments of 1,625 shares starting February 18, 2027.
What indirect AbbVie (ABBV) holdings does David Ryan Purdue report in this Form 4?
David Ryan Purdue reports 543 AbbVie shares held indirectly through a profit sharing trust in the AbbVie savings program as of February 20, 2026. This balance includes shares accumulated via a dividend reinvestment feature within the program, separate from his directly held equity awards.
How do the AbbVie (ABBV) stock options granted to David Ryan Purdue vest over time?
The 4,875-share AbbVie stock option granted to David Ryan Purdue vests in three equal annual installments. The option becomes exercisable for 1,625 shares on February 18, 2027, another 1,625 shares on February 18, 2028, and the remaining 1,625 shares on February 18, 2029.